What is CagriSema?
A combination of semaglutide and cagrilintide targeting both GLP-1 and amylin receptors for enhanced weight loss.
CagriSema (Novo Nordisk) combines two peptides in a single weekly injection: semaglutide (the GLP-1 receptor agonist behind Ozempic and Wegovy) and cagrilintide (a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells). This dual approach targets appetite and satiety through two distinct hormonal pathways that do not fully overlap. Amylin acts on the area postrema and other brain regions to promote satiety, slow gastric emptying, and suppress post-meal glucagon secretion — through mechanisms that complement but differ from GLP-1. Where GLP-1 primarily targets the hypothalamus and vagal nerve pathways, amylin operates through additional central nervous system circuits. The theory is that activating both pathways simultaneously achieves greater and more durable appetite suppression than either alone. Phase 3 REDEFINE trial results showed 22.7% body weight loss at 68 weeks — among the highest sustained weight loss seen in any obesity medication trial. For context, semaglutide alone showed approximately 15-17% in STEP trials, and cagrilintide alone showed roughly 10% in earlier studies. The combination appears genuinely synergistic rather than merely additive, suggesting the two pathways enhance each other. This represents Novo Nordisk's strategic answer to Eli Lilly's tirzepatide. Rather than pursuing a dual-receptor single molecule (as Lilly did with tirzepatide), Novo Nordisk combined their proven GLP-1 agonist with a novel amylin analog. Some researchers believe the amylin pathway may offer better muscle preservation compared to GLP-1 alone, though this needs further study. Side effects are consistent with the GLP-1 drug class — nausea, diarrhea, vomiting — though the combination may produce somewhat different GI patterns compared to semaglutide alone. FDA submission is expected in 2025, with potential approval following. If approved, CagriSema would compete directly with tirzepatide in the next-generation obesity treatment market.
What the evidence says
The overall evidence grade for CagriSema is B (moderate — mixed or smaller trials, reasonable mechanistic support). Strong Phase 3 data (REDEFINE trials). Individual components well-studied. Semaglutide has extensive approval history. Cagrilintide is novel.
Specific findings with supporting evidence:
- Phase 3 showed 22.7% weight loss at 68 weeks. Evidence grade A.
- Semaglutide component has extensive clinical data. Evidence grade A.
- Dual GLP-1/amylin pathway shows synergistic effects. Evidence grade B.
- May preserve muscle better than GLP-1 alone. Evidence grade C.
Best-supported outcomes:
- Significant weight loss rivaling tirzepatide.
- Dual-pathway appetite suppression.
- Potential synergy beyond additive effects.
Where marketing outpaces evidence:
- The claim that "FDA approved" is not supported by the evidence (grade A).
- Marketing often overstates: Proven better than tirzepatide.
- Marketing often overstates: No muscle loss.
- Marketing often overstates: Available now.
Dose and timing
Take it in the morning. Single weekly subcutaneous injection in trials. Not yet commercially available.
Who it's for, and who should skip it
Most relevant for:
- Those following next-generation obesity drug development.
- Those interested in the science of multi-pathway appetite suppression.
- Healthcare providers tracking Novo Nordisk pipeline.
Not appropriate for:
- Those needing treatment now (not yet approved).
- Those with contraindications to GLP-1 medications.
- Those looking for non-prescription options.
Safety and cautions
Caution: Not yet FDA approved. Phase 3 complete but FDA submission and review ongoing. Not available by prescription. Caution: Novel combination. While semaglutide is well-known, cagrilintide is a new molecule. Long-term safety of the combination is still being established. GI side effects. Nausea, diarrhea, vomiting consistent with GLP-1 class. Combination may produce different patterns than semaglutide alone.
Common mistakes
- Directly comparing CagriSema's Phase 3 results with tirzepatide's without accounting for trial design differences.
- Assuming semaglutide's safety record fully applies to the novel combination.
- Overlooking that cagrilintide is a new molecule with its own risk profile.
- Expecting muscle-sparing benefits before they are proven in dedicated studies.
Myths vs reality
A common misconception: CagriSema is just double-dose Wegovy. In reality, it combines semaglutide with cagrilintide (amylin analog) — a completely different hormone targeting distinct satiety pathways in the brain. The amylin component is a separate molecule, not more GLP-1. A common misconception: This makes tirzepatide obsolete. In reality, both achieve similar weight loss through different mechanisms. Individual responses vary, and tirzepatide has a head start in approvals and clinical experience. Both will likely remain relevant. A common misconception: Amylin analogs are unproven. In reality, pramlintide (Symlin), an earlier amylin analog, has been FDA-approved for diabetes since 2005. Cagrilintide is a longer-acting, more potent version of this established approach.
How it interacts with other compounds
- CagriSema works well alongside glp1 overview — gLP-1 class overview.
- CagriSema works well alongside semaglutide vs tirzepatide — comparison of current GLP-1 leaders.
- CagriSema works well alongside retatrutide — another next-gen multi-agonist approach.
Questions people ask
How does CagriSema compare to tirzepatide? CagriSema showed 22.7% weight loss at 68 weeks. Tirzepatide showed 20-22% in SURMOUNT trials. Results are in a similar range, but the mechanisms differ: CagriSema uses GLP-1 plus amylin, while tirzepatide uses GLP-1 plus GIP. Head-to-head trials would be needed for definitive comparison.
What is amylin and why add it? Amylin is a hormone released alongside insulin after meals. It promotes satiety, slows gastric emptying, and suppresses glucagon through brain circuits that differ from GLP-1. Adding it creates broader appetite suppression than GLP-1 alone.
When will CagriSema be available? FDA submission is expected in 2025. If review proceeds normally, approval and availability could follow within 12-18 months of submission. Timelines are subject to regulatory process.
Is it one injection or two? CagriSema is a single weekly injection combining both molecules. You do not need to inject semaglutide and cagrilintide separately.
Will it replace Wegovy? CagriSema will likely be positioned as a next-generation option alongside Wegovy, not necessarily a replacement. Some patients may respond adequately to semaglutide alone without needing the combination.
Does the amylin component help preserve muscle? There is theoretical reason to believe amylin pathway activation may support better muscle preservation, but this has not been conclusively demonstrated in dedicated studies. More research is needed.
Editorial note
This guide summarizes the published evidence on CagriSema. It is educational content, not medical advice. Confirm with your clinician if you take prescription medications or manage a chronic condition.